Abbott Laboratories (ABT) |
|
95.73 -1.12 (-1.16%)
|
10-02 16:01 |
|
Open: |
95.76 |
Pre. Close: |
96.85 |
|
High:
|
95.89 |
Low:
|
94.53 |
|
Volume:
|
4,069,835 |
Market Cap:
|
166,126(M) |
|
|
|
Technical analysis |
as of: 2023-10-02 3:47:32 PM |
|
Short-term rate:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
|
Mid-term rate:
|
|
| Target: |
Six months: 118.12 One year: 122.89 |
| Support: |
Support1: 94.52 Support2: 78.64 |
| Resistance: |
Resistance1: 101.13 Resistance2: 105.22 |
| Pivot: |
99.2 |
| Moving Average: |
MA(5): 96.42 MA(20): 99.71
MA(100): 105.2 MA(250): 105.16 |
| MACD: |
MACD(12,26): -2.2 Signal(9): -1.9 |
| Stochastic oscillator: |
%K(14,3): 23.6  %D(3): 21.1 |
| RSI: |
RSI(14): 30.5 |
| 52-week: |
High: 115.83 Low: 93.25 |
| Average Vol(K): |
3-Month: 4,439 (K) 10-Days: 4,331 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ABT ] has closed above bottom band by 12.0%. Bollinger Bands are 35.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
98.79 - 99.34 |
99.34 - 99.78 |
|
Low:
|
94.78 - 95.56 |
95.56 - 96.19 |
|
Close:
|
95.71 - 96.86 |
96.86 - 97.8 |
|
Company Description |
|
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois. |
Headline News |
Mon, 02 Oct 2023
3 Medical Product Stocks With Solid Dividend Yield: ABT & Others - Nasdaq
Sun, 01 Oct 2023
Abbott Laboratories (NYSE:ABT) Stake Lifted by Osborne Partners ... - MarketBeat
Fri, 29 Sep 2023
Abbott Laboratories stock falls Friday, underperforms market - MarketWatch
Fri, 29 Sep 2023
Abbott Laboratories And More On CNBC’s ‘Final Trades’ - Abbott Laboratories (NYSE:ABT), Innovator U.S. Eq - Benzinga
Fri, 29 Sep 2023
Zacks Research Research Analysts Lift Earnings Estimates for Abbott Laboratories (NYSE:ABT) - MarketBeat
Fri, 29 Sep 2023
Abbott Laboratories Stock Triumphs Over Challenges: A Tale Of Resilience (NYSE:ABT) - Seeking Alpha
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Medical Devices |
| Shares Out. |
1,740 (M) |
| Shares Float |
1,720 (M) |
|
% Held by Insiders
|
0.5 (%) |
|
% Held by Institutions
|
76.3 (%) |
|
Shares Short
|
11,470 (K) |
|
Shares Short P.Month
|
12,050 (K) |
Stock Financials |
|
EPS
|
2.93 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
21.42 |
|
Profit Margin (%)
|
12.8 |
|
Operating Margin (%)
|
16.6 |
|
Return on Assets (ttm)
|
5.6 |
|
Return on Equity (ttm)
|
13.9 |
|
Qtrly Rev. Growth
|
-11.4 |
|
Gross Profit (p.s.)
|
14.12 |
|
Sales Per Share
|
23.12 |
|
EBITDA (p.s.)
|
5.69 |
|
Qtrly Earnings Growth
|
-31.7 |
|
Operating Cash Flow
|
7,450 (M) |
|
Levered Free Cash Flow
|
5,710 (M) |
Stock Valuations |
|
PE Ratio
|
32.55 |
|
PEG Ratio
|
-11 |
|
Price to Book value
|
4.45 |
|
Price to Sales
|
4.12 |
|
Price to Cash Flow
|
22.27 |
Stock Dividends |
|
Dividend
|
0.5 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0.5% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
